Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Looking To Patient Advocates To Answer Benefit-Risk Questions

This article was originally published in RPM Report

Executive Summary

FDA’s clinical review teams are starting to approve novel drugs and biologics using a new structured benefit-risk framework developed under PDUFA V. Those assessments ask reviewers to think more broadly about the disease and how a new treatment might fit into the current treatment model. But many reviewers don’t have that information. And that, FDA says, is where patient advocates come in.

Advertisement

Related Content

FDA Breast Cancer Patient Meeting Likely To Examine Differences Between Early-Stage and Metastatic Experiences
Provectus Breakthrough Denial Is Symptom Of a Different Breakthrough at FDA
FDA Needs Formal Mechanism To Integrate Patient Input, Groups Say
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
20 Is The Loneliest Number: FDA Disease Meeting Schedule Leaves Some Worried About Exclusion
Disease-Of-The-Quarter Club: FDA Plans 20 Patient Network Meetings Over Five Years
Getting a Jump on PDUFA V: Fast Start on REMS, Patient Input – And Longer Reviews
Patient Advocacy 3.0: Outreach Stretches to First Stages of Regulatory Development
FDA "Grids" for More Transparent Risk-Benefit Decision
Big Pharma and Orphan Drugs: The Case for Thinking Small

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel